FY2026 Earnings Forecast for BMY Issued By Erste Group Bank

Bristol Myers Squibb Company (NYSE:BMY) – Erste Group Bank upped their FY2026 EPS estimates for shares of Bristol Myers Squibb in a research note issued on Wednesday, August 5th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will earn $6.96 per share for the year, up from their prior estimate of $6.34. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.96 per share. Erste Group Bank also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $6.51 EPS.

BMY has been the subject of several other reports. Sanford C. Bernstein upgraded Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Bank of America decreased their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Wells Fargo & Company set a $65.00 price objective on Bristol Myers Squibb and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Citigroup reaffirmed a “neutral” rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Finally, UBS Group lowered Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $64.75 on Tuesday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $68.10. The company has a 50 day moving average price of $58.91 and a two-hundred day moving average price of $58.74. The stock has a market capitalization of $132.27 billion, a PE ratio of 14.26, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the prior year, the firm earned $1.46 EPS. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BMY. Swiss RE Ltd. bought a new stake in Bristol Myers Squibb in the 4th quarter valued at $25,000. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $25,000. Physician Wealth Advisors Inc. boosted its position in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares in the last quarter. Bayban bought a new stake in Bristol Myers Squibb in the fourth quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb in the fourth quarter worth about $32,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Major Houston manufacturing investment: BMY plans to invest approximately $2.3 billion in a roughly 600,000-square-foot manufacturing campus at Generation Park in Houston. The facility is expected to create nearly 500 permanent jobs and approximately 2,000 construction positions. The project expands domestic production capacity and is part of the company’s previously announced $40 billion U.S. investment commitment, supporting the company’s long-term operating and supply-chain strategy. Bristol Myers to build $2.3 billion manufacturing site in Houston
• Positive Sentiment: Broker sentiment remains constructive: Brokerages currently assign BMY an average recommendation of “Moderate Buy,” suggesting analysts generally view the stock favorably despite some concerns about future growth and competition. Bristol Myers Squibb Receives Average Recommendation of Moderate Buy
• Neutral Sentiment: Recent performance has improved, but valuation requires caution: BMY has rallied about 16% over the past three months, supported by its growth portfolio and pipeline. Analysts say the momentum is encouraging, but the stock’s recent advance may limit near-term upside. BMY Rallies 16.2% in Three Months
• Negative Sentiment: Generic competition remains an overhang: While BMY’s pipeline and portfolio support the longer-term outlook, upcoming patent losses and generic competition could pressure revenue and earnings, making investors more cautious after the recent share-price gains. BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.